A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

  • End date
    Feb 26, 2024
  • participants needed
  • sponsor
Updated on 25 March 2022


This is a modular Phase I/IIa, open-label, multi-centre, study of AZD7648 administered orally, either as a monotherapy, or in combination with either cytotoxic chemotherapies or novel anti-cancer agents in participants with advanced malignancies.


The modular design allows for an escalation of the dose of AZD7648 alone or in combination with either cytotoxic chemotherapies or novel anti-cancer agents, with intensive safety monitoring to ensure the safety of the participants.

The study consists of 2 modules each evaluating the safety and tolerability of AZD7648 monotherapy or with a specific combination partner.

Core module of the study is dose escalation (Part A) of AZD7648 monotherapy, administered orally, in participants with advanced solid tumours.

Combination module 1 has 2 study parts: Part A consisting of dose escalation cohorts and Part B, a safety and proof of concept Phase IIa expansion. A Safety Review Committee will review evaluable participants at each cohort and assess if the study should progress to Part B.

Condition Advanced Malignancies
Treatment olaparib, Pegylated Liposomal Doxorubicin (PLD), PLD, AZD7648
Clinical Study IdentifierNCT03907969
Last Modified on25 March 2022


Yes No Not Sure

Inclusion Criteria

Capable and willing to give signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF)
Participant must be at least 18 years of age, at the time of signing the ICF
Participants must have histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment
Eastern cooperative oncology group performance status 0-1
Life expectancy greater than 12 weeks
Progressive cancer at the time of study entry
Pharmacodynamics expansion cohorts: Participants must have at least 1 tumour suitable for biopsy and consent to having biopsies collected
Negative pregnancy test (urine or serum) prior to start of dosing for women of childbearing potential
Female participants must be post-menopausal, surgically sterile, or using an acceptable method of contraception for the duration of the study (from the time they sign consent) and for 12 weeks after the last dose of study treatment to prevent pregnancy
For the duration of the study (from the time they sign consent) and for 12 weeks after the last dose of study treatment, sexually active male participants must be willing to use contraception
Post-menopausal is defined as
No menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy). However in the absence of 12 months of amenorrhea, a FSH measurement is insufficient
Radiation-induced oophorectomy with last menses greater than 12 months ago
Chemotherapy-induced menopause with greater than 12 month interval since last menses
Surgical sterilisation

Exclusion Criteria

Any unresolved toxicities from prior therapy common terminology criteria for adverse event (CTCAE) Grade ≥2 (with the exception of alopecia)
Spinal cord compression or brain metastases unless definitively treated, asymptomatic, stable and not requiring steroids for at least 4 weeks
As judged by the Investigator, any evidence of severe or uncontrolled medical conditions including but not limited to
• Uncontrolled diabetes mellitus, uncontrolled seizures, active infection
requiring systemic antibiotics, antifungal or antiviral drugs, severe chronic
obstructive pulmonary disease, severe Parkinson's disease, active inflammatory
bowel disease, psychiatric condition, active bleeding diatheses, renal
transplant, or active infection including any participant with active
hepatitis B, hepatitis C or human immunodeficiency virus
Any other malignancy which has been active or treated within the past 3 years, with the exception of in situ cancer of the cervix, non-melanoma skin cancer, ductal carcinoma in situ, Stage 1 Grade 1 endometrial carcinoma, or other solid tumours including lymphomas curatively treated with no evidence of disease for ≥5 years
Refractory nausea and vomiting or unable to swallow and retain oral medication, chronic gastrointestinal diseases or previous bowel resection with clinically significant sequelae that would preclude adequate absorption of AZD7648, gastrointestinal symptoms CTCAE Grade >1, history of gastrointestinal ulceration and gastrointestinal haemorrhage within 6 months of first study drug administration
Receiving or having received anti-cancer treatment within the following periods prior to
the first dose of investigational product
(a) Cytotoxic treatment: 3 weeks, (b) Non-cytotoxic drugs: including small molecule
investigational products: 3 weeks or 5 half-lives (whichever is longest), (c) Biological
products including investigational immuno-oncology agents: 4 weeks, (d) Radiation with a
limited field for palliation: 1 week (3 months for radiation to the abdomen or pelvis), (e)
Radiation to >30% of the bone marrow or with a wide field: 4 weeks, (f) Lung radiation: 60
days, (g) Major surgery: 4 weeks; minor surgery or biopsy: 1 week 7. During the 4 weeks
prior to the first dose, receiving corticosteroids at a dose of >10 mg prednisone/day or
equivalent for any reason. Ongoing low dose steroids for longer than 3 months (excluding
inhalational, nasal, creams, lotions, and gels) are not allowed
Receiving or having received concomitant medications, herbal supplements and/or foods
known to significantly modulate CYP3A4 activity
Prior exposure to a deoxyribonucleic acid-pharmacokinetics inhibitor or hypersensitivity
to any excipient of the product
Cardiac dysfunction as defined by any of the following within 6 months of study entry
(a) Acute myocardial infarction, (b) New York Heart Association Class II/III/IV heart
failure, (c) Unstable angina, (d) Unstable cardiac arrhythmias 11. Any of the following
cardiac criteria
(a) Known reduced left ventricular ejection fraction below the institutional lower limit of
normal, (b) Mean resting corrected QT interval (QTc) >470 milliseconds obtained from 3
electrocardiograms in 24 hours using the Fridericia formula, (c) Any factors that increase
the risk of QTc prolongation or arrhythmic events such as hypokalaemia, congenital long QT
syndrome, immediate family history of long QT syndrome or unexplained sudden death under 40
years of age 12. Inadequate hematological or organ function 13. Involvement in the planning
and/or conduct of the study. 14. Judgement by the Investigator that the participant should
not participate in the study if the participant is unlikely to comply with study
procedures, restrictions and requirements
Previous enrolment in the present study. 16. For female participant only: currently
pregnant or breast-feeding. 17. For food effect cohort only: insulin dependent diabetes
History and/or presence of coronavirus disease 2019
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note